ESR1 and breast carcinoma: Similarly, a compound called N-[(2Z)-3-(4,5-dihydro-1,3-thiazol-2-yl)-1,3-thiazolidin-2-yl idene]-5H dibenzo [a, d] [7] annulen-5-amine was found inhibiting the proliferation of both ER+ and ER- breast cancer cells through the inhibition of ERRα signaling [15].